Bayer's Eylea hits main goal in DME trials

In two Phase III trials, Bayer's VEGF Trap-Eye drug, also called Eylea, met its primary endpoint in treating diabetic macular edema, the company said. The firm co-develops the medication with Regeneron, which plans to seek U.S. marketing approval this year for the treatment of diabetic macular edema.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA